{"id":16,"date":"2022-09-19T07:00:23","date_gmt":"2022-09-19T07:00:23","guid":{"rendered":"https:\/\/sites.medicalupdateonline.com\/urologyweek2022\/?page_id=16"},"modified":"2023-03-09T16:00:13","modified_gmt":"2023-03-09T16:00:13","slug":"urology-week-2022","status":"publish","type":"page","link":"https:\/\/sites.medicalupdateonline.com\/urologyweek2022\/","title":{"rendered":"Urology Week 2022"},"content":{"rendered":"

Every year the European Association of Urology (EAU) hosts Urology Week, an international campaign for increasing awareness of urological conditions and treatment.<\/p>\n

This year,\u00a0Urology Week<\/a>\u00a0(26-30 September 2022) is focused on blood in urine as an indicator for bladder cancer.<\/p>\n

\"\"<\/p>\n

To coincide with Urology Week we present a series of articles and video interviews relating to bladder cancer from the recent EAU congress.<\/p>\n\n\n\n\n\n
\"\"<\/a><\/p>\n

Why bladder cancer matters<\/strong><\/a><\/p>\n

Bladder cancer is the 5th most common tumour in men and the 7-8th most common tumour women, according to Professor Arnulf Stenzl, Head of the Department of Urology in the\u2026 read more.<\/strong><\/a><\/td>\n

\"\"<\/a><\/p>\n

Re-TUR: depends on surgeon skill or tumour biology?<\/strong><\/a><\/p>\n

Current guidelines recommend a repeat TUR (re-TUR) for T1 bladder tumours but this carries risks and could be avoided if a good, complete TUR is done in the\u2026 read more.<\/strong><\/a><\/td>\n

\"\"<\/a><\/p>\n

Cystectomy vs trimodality bladder preserving treatment for muscle invasive bladder cancer (MIBC)<\/strong><\/a><\/p>\n

According to the updated EAU guidelines long-term survival with trimodality bladder preserving treatment (TMT) could be as good as with radical cystectomy (RC), in selected patients. During the\u2026 read more.<\/strong><\/a><\/td>\n<\/tr>\n

\"\"<\/a><\/p>\n

Trimodality therapy for MIBC \u2013 present and future directions<\/strong><\/a><\/p>\n

Trimodality bladder preserving treatment (TMT) for muscle invasive bladder cancer is gaining ground but careful patient selection is essential for success \u2013 only 10-20 percent of cases fit\u2026 read more.<\/strong><\/a><\/td>\n

\"\"<\/a><\/p>\n

Bladder-sparing strategies in the management of muscle-invasive bladder cancer<\/strong><\/a><\/p>\n

For many years surgery has been regarded as the gold standard for MIBC but now comparative trials, epidemiological findings and a meta-analysis of trials all show that outcomes\u2026 read more.<\/strong><\/a><\/td>\n

\"\"<\/a><\/p>\n

Current trials with intravesical treatment in high-risk BCG-na\u00efve NMIBC<\/strong><\/a><\/p>\n

Intravesical therapy with chemotherapy or BCG is the recommended adjuvant treatment after TURBT to minimise the risk of recurrence. BCG shortages continue and BCG is not suitable for\u2026 read more.<\/strong><\/a><\/td>\n<\/tr>\n

\"\"<\/a><\/p>\n

En bloc resection vs TURBT for NMIBC<\/strong><\/a><\/p>\n

The traditional surgical technique for TURBT involves piecemeal removal of the tumour whereas en bloc resection (ERBT) removes the whole tumour in one piece. Professor J\u00f8rgen Bjerggaard Jensen (Aarhus, Denmark)\u2026 read more.<\/strong><\/a><\/td>\n

\"\"<\/a><\/p>\n

Immunotherapy: Adjuvant immune checkpoint inhibitors for everybody?<\/strong><\/a><\/p>\n

The introduction of immunotherapy with immune checkpoint inhibitors has improved outcomes in trials. In this video Professor Morgan Roupret explains the current situation regarding immunotherapy and bladder cancer: This session\u2026 read more.<\/a><\/strong><\/td>\n

\"\"<\/a><\/p>\n

Lynch syndrome \u2013 what urologists need to know<\/a><\/strong><\/p>\n

Lynch syndrome, an inherited cancer syndrome, has been prominently associated with colorectal cancer but other organs, including the urinary tract can also be affected. As a hereditary condition,\u2026 read more.<\/strong><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Bladder cancer in the UK \u2013 key points<\/strong><\/p>\n

According to Cancer Research UK:<\/p>\n